Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-08-25 M&A Activity
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
M&A Activity Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used in the context of a takeover or merger activity to disclose significant holdings and dealings by parties involved. This strongly aligns with the definition of M&A Activity (TAR), which covers merger proposals or takeover bids, as Form 8.3 is a mandatory disclosure during such events in the UK (governed by the Takeover Code). It is not a general regulatory filing (RNS) because it is highly specific to takeover rules, nor is it a Director's Dealing report (DIRS) as it pertains to a large investment manager (Millennium International Management LP) in relation to an offer, not necessarily a director's personal trade.
2023-08-25 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". Form 8.3 is a mandatory disclosure required under the UK Takeover Code when a person holding interests in relevant securities representing 1% or more makes a dealing during an offer period. This form discloses the person's opening position or dealing activity related to the offer. This specific type of disclosure, dealing by a major shareholder/stakeholder during a takeover scenario, is best categorized as a notification related to insider/significant shareholder transactions, which aligns most closely with the 'Director's Dealing' (DIRS) category, as it tracks significant personal/related party transactions in securities, even though it is specifically a Takeover Code filing. Since there is no specific code for 'Takeover Disclosure', and it involves reporting interests/dealings by a major party, DIRS is the closest fit among the provided options, although it is broader than just directors. Given the context of dealing disclosure, DIRS is selected over the general RNS.
2023-08-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 3750K' on August 24, 2023. This form is used to report changes in significant share ownership (crossing thresholds) by institutional investors or large shareholders, which falls under regulatory disclosure requirements concerning major shareholdings. This directly corresponds to the definition for Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is the more specific category for this type of disclosure.
2023-08-24 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of M&A activity or specific regulatory disclosures related to takeovers. Since there is a specific category for M&A Activity (TAR), and this disclosure is directly tied to a takeover context (referencing the Takeover Code and an offeror/offeree), TAR is the most appropriate classification, as it covers merger proposals or takeover bids. It is not a general Director's Dealing (DIRS) as it is specific to a takeover event under the Takeover Code rules.
2023-08-23 English
Rule 2.9 Announcement
M&A Activity Classification · 99% confidence The document is identified by the header 'RNS Number : 1184K' and explicitly mentions 'Rule 2.9 Announcement' under the 'City Code on Takeovers and Mergers (the "Code")'. This type of announcement, which confirms the total number of shares in issue during an offer period, is a specific regulatory disclosure related to potential M&A activity or corporate control changes. While it relates to takeovers (TAR), the specific nature of confirming share capital under Rule 2.9 of the UK Takeover Code often falls under general regulatory announcements or specific M&A related disclosures. Given the context of the City Code and the confirmation of share capital during an offer period, it is most closely related to M&A Activity (TAR) or, if that is too specific, a general Regulatory Filing (RNS). Since the content is a direct regulatory disclosure mandated by the Takeover Code regarding share structure during an offer period, it strongly aligns with the context of M&A Activity (TAR). However, Rule 2.9 announcements are often categorized broadly. Given the explicit mention of the Takeover Code and the focus on share capital in the context of an offer, TAR is plausible, but RNS is the safest general regulatory category for non-standard, mandatory disclosures like this. Since the document is a formal, mandatory disclosure under the Takeover Code, and the definitions do not explicitly cover 'Rule 2.9 Announcement', I will classify it as a general Regulatory Filing (RNS) as it is a standard regulatory notification service output (RNS) that doesn't fit 10-K, ER, or IR, and is not a proxy statement (PSI) or dividend notice (DIV). The document is short and is a direct regulatory update, not an announcement *of* a report.
2023-08-22 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of M&A activity or significant shareholding notifications, but the specific nature of reporting director/insider dealings during a takeover context aligns most closely with the intent behind tracking insider transactions. Reviewing the definitions: - DIRS (Director's Dealing): Report of personal share transactions by company directors and executives (insider trades). - MRQ (Major Shareholding Notification): Notification of changes in significant share ownership levels (crossing thresholds). - TAR (M&A Activity): Announcements and documents related to merger proposals or takeover bids. Since this is a mandatory disclosure under the Takeover Code (Rule 8.3) concerning interests in securities during an ongoing offer, it is a specific type of insider/major shareholder disclosure related to M&A. While it involves share interests (like MRQ), the context is explicitly the 'Takeover Code'. Given the options, 'Director's Dealing' (DIRS) covers insider transactions, and 'M&A Activity' (TAR) covers the context. However, Form 8.3 is a specific disclosure required of any person (not just directors) holding 1% or more during an offer. In many classification schemes, specific takeover disclosures are grouped with M&A activity (TAR) or sometimes treated as a specialized insider filing. Since the document details the positions and dealings of Millennium International Management LP concerning the offer for Dechra Pharmaceuticals plc, it is fundamentally an M&A-related disclosure regarding ownership stakes during the bid process. If TAR is interpreted broadly as 'Takeover Activity', it fits best. If we strictly interpret DIRS as only 'Directors', then TAR is the next best fit due to the explicit reference to the Takeover Code and the offeror/offeree structure.
2023-08-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.